BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
McKinsey
Harvard Business School
Chubb
Chinese Patent Office
Fuji
Federal Trade Commission
Express Scripts
Dow
Johnson and Johnson

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,878,749

« Back to Dashboard

Which drugs does patent 6,878,749 protect, and when does it expire?

Patent 6,878,749 protects STARLIX and is included in one NDA.

This patent has forty-two patent family members in thirty countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.
Summary for Patent: 6,878,749
Title: Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
Abstract:The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises nateglinide (1) stet ##STR1## or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases and conditions associated with diabetes; to a composition, respectively, which comprises nateglinide and a pharmaceutically acceptable carrier and to a process of making such composition; the use of such combination or composition for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders; a method of prevention, delay of progression or treatment of diseases in warm-blooded animals; the use of such combination or composition for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight; and to a method of improving the bodily appearance of a warm-blooded animal.
Inventor(s): Gatlin; Marjorie Regan (Hoboken, NJ), Ball; Michele Ann (Morris Plains, NJ), Mannion; Richard Owen (Mount Arlington, NJ), Karnachi; Anees Abdulquadar (Hillsborough, NJ), Guitard; Christiane (Hegenheim, FR), Allison; Malcolm (Basel, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:10/345,908
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Drugs Protected by US Patent 6,878,749

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis STARLIX nateglinide TABLET;ORAL 021204-001 Dec 22, 2000 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis STARLIX nateglinide TABLET;ORAL 021204-002 Dec 22, 2000 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,878,749

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0021055Aug 26, 2000

Non-Orange Book US Patents Family Members for Patent 6,878,749

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,559,188 Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,878,749

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I278312 ➤ Subscribe
Taiwan 200401631 ➤ Subscribe
Taiwan I278311 ➤ Subscribe
Slovakia 3602002 ➤ Subscribe
Singapore 127714 ➤ Subscribe
Russian Federation 2280447 ➤ Subscribe
Poland 354168 ➤ Subscribe
Peru 07392001 ➤ Subscribe
New Zealand 528738 ➤ Subscribe
New Zealand 517280 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Teva
Harvard Business School
Colorcon
Federal Trade Commission
Daiichi Sankyo
Accenture
Fuji
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot